Last reviewed · How we verify
L-Tretoquinol (TRETOQUINOL)
L-Tretoquinol (generic name: TRETOQUINOL) is a tretoquinol drug. It is currently in Phase 2 development.
L-Tretoquinol works by binding to the Beta-1 adrenergic receptor, which is involved in regulating heart rate and blood pressure.
L-Tretoquinol is a small molecule with the synonyms DL-TRIMETOQUINOL, INOLIN, NSC-288748, RACEMIC-TRIMETOQUINOL, RO-07-5965, and S-(-)-TRETOQUINOL. No specific information is available on its clinical indications or mechanism of action from the provided sources.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TRETOQUINOL |
|---|---|
| Drug class | tretoquinol |
| Target | Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Thromboxane A2 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Think of it like a key fitting into a lock. L-Tretoquinol is the key that binds to the Beta-1 adrenergic receptor, which is like a lock on the surface of heart cells. When the key fits into the lock, it sends a signal that can affect how the heart beats and how blood pressure is regulated.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Tretoquinol CI brief — competitive landscape report
- L-Tretoquinol updates RSS · CI watch RSS
Frequently asked questions about L-Tretoquinol
What is L-Tretoquinol?
How does L-Tretoquinol work?
What is the generic name of L-Tretoquinol?
What drug class is L-Tretoquinol in?
What development phase is L-Tretoquinol in?
What does L-Tretoquinol target?
Related
- Drug class: All tretoquinol drugs
- Target: All drugs targeting Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Thromboxane A2 receptor
- Therapeutic area: All drugs in Cardiovascular
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing